other_material
confidence high
sentiment positive
materiality 0.70
Monopar announces Phase 2 publication: ALXN1840 improves copper balance in Wilson disease
Monopar Therapeutics
- Cumulative mean decrease in copper balance of -6.08 mg over 21 days (95% CI: -10.18 to -1.98 mg).
- Mean daily change of -0.37 mg (p=0.005) on 15 mg/day dosing; -0.29 mg (p=0.023) overall.
- ~50% increase in fecal copper output-to-intake ratio vs baseline (p=0.041).
- ALXN1840 well tolerated; no serious adverse events reported in the single-arm Phase 2 trial.
- Improvements seen even in patients with mean 16 years prior standard-of-care treatment.
item 7.01item 9.01